Last reviewed 2026-05-22 · How we verify

SULFOMYXIN

FDA-approved active Recombinant protein ✓ Verified May 2026 Quality 6/100

SULFOMYXIN is a drug. It is currently FDA-approved.

Sulfomyxin is a protein modality. It is also known by other names, including Dynamyxin, GS-6742, Sulfomixina, and Sulfomyxine.

At a glance

Generic name	SULFOMYXIN
Modality	Recombinant protein
Therapeutic area	Metabolic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SULFOMYXIN CI brief — competitive landscape report
SULFOMYXIN updates RSS · CI watch RSS

Frequently asked questions about SULFOMYXIN

What is SULFOMYXIN?

SULFOMYXIN is a Recombinant protein drug.

What development phase is SULFOMYXIN in?

SULFOMYXIN is FDA-approved (marketed).

Therapeutic area: All drugs in Metabolic

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing